MK-431 (Merck).
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
MK-431 (Merck). / Deacon, Carolyn F.
In: Current Opinion in Investigational Drugs, Vol. 6, No. 4, 2005, p. 419-26.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - MK-431 (Merck).
AU - Deacon, Carolyn F
N1 - Keywords: Adenosine Deaminase; Animals; Antigens, CD26; Clinical Trials as Topic; Drug Industry; Glycoproteins; Humans; Hypoglycemic Agents; Protease Inhibitors; Pyrazines; Triazoles
PY - 2005
Y1 - 2005
N2 - Merck & Co is developing MK-431, the lead from a series of dipeptidyl peptidase IV inhibitors that enhance endogenous glucagon-like peptide-1 levels, for the potential treatment of type 2 diabetes. Phase III studies were initiated in the second quarter of 2004.
AB - Merck & Co is developing MK-431, the lead from a series of dipeptidyl peptidase IV inhibitors that enhance endogenous glucagon-like peptide-1 levels, for the potential treatment of type 2 diabetes. Phase III studies were initiated in the second quarter of 2004.
M3 - Journal article
C2 - 15898349
VL - 6
SP - 419
EP - 426
JO - Current Opinion in Investigational Drugs
JF - Current Opinion in Investigational Drugs
SN - 1354-3784
IS - 4
ER -
ID: 8417240